Shree Ganesh Remedies Ltd is Rated Sell

Understanding the Current Rating

The 'Sell' rating assigned to Shree Ganesh Remedies Ltd indicates a cautious stance for investors, suggesting that the stock may underperform relative to the broader market or its sector peers in the near to medium term. This recommendation is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the stock's investment potential.

Quality Assessment

As of 25 August 2026, Shree Ganesh Remedies Ltd holds an average quality grade. This reflects moderate operational efficiency and business fundamentals. Over the past five years, the company has demonstrated a net sales growth rate of 13.40% annually, which, while positive, is considered modest within the Pharmaceuticals & Biotechnology sector. Operating profit growth has been slightly lower at 10.23% per annum, indicating some pressure on margins or cost structures.

However, recent quarterly results have been disappointing. The company reported a sharp decline in net sales by 41.79% in June 2026, accompanied by a significant fall in profit before tax excluding other income (PBT LESS OI) by 85.03% to ₹0.59 crore and a 67.5% drop in profit after tax (PAT) to ₹1.12 crore. These figures highlight challenges in sustaining profitability and operational momentum.

Valuation Considerations

Currently, the stock is considered expensive, with a valuation grade reflecting this status. The price-to-book value stands at 4.1, which is high relative to typical benchmarks in the sector. Despite this, the stock trades at a discount compared to its peers' average historical valuations, suggesting some relative value may exist. The return on equity (ROE) is 10.9%, which is moderate but does not fully justify the elevated valuation multiple.

Investors should note that over the past year, the stock has delivered a negative return of 14.21%, while profits have declined by 29.5%. This disconnect between valuation and earnings performance is a key factor in the cautious rating.

Financial Trend Analysis

The financial trend for Shree Ganesh Remedies Ltd is very negative as of 25 August 2026. The company’s half-year return on capital employed (ROCE) is at a low 14.23%, signalling inefficient capital utilisation. The recent sharp declines in sales and profits further underscore the deteriorating financial health. Additionally, the stock’s performance over various time frames has been weak, with a one-month decline of 21.16%, three-month decline of 22.46%, and a six-month decline of 2.15%. Although the year-to-date return is positive at 9.45%, the longer-term trend remains unfavourable.

Technical Outlook

From a technical perspective, the stock is rated as sideways, indicating a lack of clear directional momentum. The recent price movements show volatility and a lack of sustained upward trends. The one-day change of -2.27% and one-week decline of 3.67% reflect short-term selling pressure. This sideways technical grade suggests that the stock may continue to trade within a range without significant breakout potential in the immediate term.

Stock Returns and Market Performance

As of 25 August 2026, Shree Ganesh Remedies Ltd has underperformed key market indices and its sector peers. The stock’s one-year return of -14.21% contrasts with the broader BSE500 index, which has shown more resilience over the same period. The stock has also lagged behind in the three-year and three-month time frames, indicating persistent underperformance. This trend is a critical consideration for investors evaluating the stock’s risk and reward profile.

Summary for Investors

In summary, the 'Sell' rating for Shree Ganesh Remedies Ltd reflects a combination of average quality, expensive valuation, very negative financial trends, and sideways technicals. Investors should approach this stock with caution, recognising the challenges the company faces in terms of profitability and market performance. The rating suggests that there may be better opportunities elsewhere in the Pharmaceuticals & Biotechnology sector or broader market, especially given the stock’s recent underperformance and valuation concerns.

Company Profile and Market Capitalisation

Shree Ganesh Remedies Ltd operates within the Pharmaceuticals & Biotechnology sector and is classified as a microcap company. This classification indicates a relatively small market capitalisation, which can contribute to higher volatility and liquidity risks. Investors should factor in these considerations when assessing the stock’s suitability for their portfolios.

Mojo Score and Grade Context

The company’s current Mojo Score stands at 31.0, which corresponds to a 'Sell' grade. This score improved from a previous 'Strong Sell' rating with a score of 26, reflecting a modest positive shift in the company’s outlook as of 17 August 2026. Despite this improvement, the score remains low, signalling ongoing concerns about the stock’s investment appeal.

Conclusion

For investors, the 'Sell' rating on Shree Ganesh Remedies Ltd serves as a cautionary signal. The combination of average operational quality, expensive valuation, deteriorating financial trends, and lacklustre technical momentum suggests limited upside potential in the near term. While the company has shown some resilience in its year-to-date returns, the broader picture points to challenges that may weigh on shareholder value. Careful monitoring of quarterly results and sector developments is advisable for those holding or considering this stock.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →